文献リスト

1) Tanaka K, Shimada H, Matsumoto C, et al. Anatomic versus limited nonanatomic resection for solitary hepatocellular carcinoma. Surgery. 2008; 143: 607-15

2) Eguchi S, Kanematsu T, Arii S, et al. Liver Cancer Study Group of Japan. Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery. 2008; 143: 469-75

3) Kobayashi A, Miyagawa S, Miwa S, et al. Prognostic impact of anatomical resection on early and late intrahepatic recurrence in patients with hepatocellular carcinoma. J Hepatobiliary Pancreat Surg. 2008; 15: 515-21

4) Nanashima A, Sumida Y, Abo T, et al. Comparison of survival between anatomic and non-anatomic liver resection in patients with hepatocellular carcinoma: significance of surgical margin in non-anatomic resection. Acta Chir Belg. 2008; 108: 532-7

5) Shimada K, Sakamoto Y, Esaki M, et al. Role of the width of the surgical margin in a hepatectomy for small hepatocellular carcinomas eligible for percutaneous local ablative therapy. Am J Surg. 2008; 195: 775-81

6) Liu P, Yang JM, Niu WY, et al. Prognostic factors in the surgical treatment of caudate lobe hepatocellular carcinoma. World J Gastroenterol. 2010; 16: 1123-8

7) Gotoh K, Yamada T, Ishikawa O, et al. A novel image-guided surgery of hepatocellular carcinoma by indocyanine green fluorescence imaging navigation. J Surg Oncol. 2009; 100: 75-9

8) Zhou WP, Lai EC, Li AJ, et al. A prospective, randomized, controlled trial of preoperative transarterial chemoembolization for resectable large hepatocellular carcinoma. Ann Surg. 2009; 249: 195-202

9) Itoh S, Morita K, Ueda S, et al. Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas. Ann Surg Oncol. 2009; 16: 3299-307

10) Cheung TT, Ng KK, Chok KS, et al, Combined resection and radiofrequency ablation for multifocal hepatocellular carcinoma: prognosis and outcomes. World J Gastroenterol. 2010; 16: 3056-62

11) Lau WY, Lai EC, Leung TW, et al. Adjuvant intra-arterial iodine-131-labeled lipiodol for resectable hepatocellular carcinoma: a prospective randomized trial-update on 5-year and 10-year survival. Ann Surg. 2008; 247: 43-8

12) Ng KM, Niu R, Yan TD, et al. Adjuvant lipiodol I-131 after curative resection/ablation of hepatocellular carcinoma. HPB (Oxford). 2008; 10: 388-95

13) Xia Y, Qiu Y, Li J, et al. Adjuvant therapy with capecitabine postpones recurrence of hepatocellular carcinoma after curative resection: A randomized controlled trial. Ann Surg Oncol. 2010 Jul 3 [Epub ahead of print]

14) Imura S, Ikemoto T, Morine Y, et al. Effect of a new adjuvant systemic interferon alpha, 5-fluorouracil and cisplatin on advanced hepatocellular carcinoma with macroscopic portal invasion. Hepatogastroenterology. 2008; 55: 615-20

15) Hui D, Qiang L, Jian W, et al. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis. 2009; 41: 36-41

16) Zhang CH, Xu GL, Jia WD, et al. Effects of interferon alpha treatment on recurrence and survival after complete resection or ablation of hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Int J Cancer. 2009; 124: 2982-8

17) Breitenstein S, Dimitroulis D, Petrowsky H, et al. Systematic review and meta-analysis of interferon after curative treatment of hepatocellular carcinoma in patients with viral hepatitis. Br J Surg. 2009; 96: 975-81

18) Singal AK, Freeman Jr DH, Anand BS. Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma. Aliment Pharmacol Ther. 2010 Jul 26 [Epub ahead of print]

19) Ruzzenente A, Capra F, Pachera S, et al. Is liver resection justified in advanced hepatocellular carcinoma？ Results of an observational study in 464 patients. J Gastrointest Surg. 2009; 13: 1313-20

20) Schiffman SC, Woodall CE, Kooby DA, et al. Factors associated with recurrence and survival following hepatectomy for large hepatocellular carcinoma: a multicenter analysis. J Surg Oncol. 2010; 101: 105-10

21) Ng KM, Yan TD, Black D, et al. Prognostic determinants for survival after resection/ablation of a large hepatocellular carcinoma. HPB (Oxford). 2009; 11: 311-20

22) Shinkawa H, Uenishi T, Takemura S, et al. Risk factors for postoperative recurrence of non-B non-C hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2010; 17: 291-5

23) Shiba H, Ishida Y, Wakiyama S, et al. Negative impact of blood transfusion on recurrence and prognosis of hepatocellular carcinoma after hepatic resection. J Gastrointest Surg. 2009; 13: 1636-42

24) Fujiwara Y, Shiba H, Furukawa K, et al. Perioperative change in white blood cell count predicts outcome of hepatic resection for hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2010 May 7 [Epub ahead of print]

25) Furihata T, Sawada T, Kita J, et al. Serum alpha-fetoprotein level per tumor volume reflects prognosis in patients with hepatocellular carcinoma after curative hepatectomy. Hepatogastroenterology. 2008; 55 1705-9

26) Wang DD, Zhao YM, Wang L, et al. Preoperative serum retinol-binding protein 4 is associated with the prognosis of patients with hepatocellular carcinoma after curative resection. J Cancer Res Clin Oncol. 2010 Jun 15 [Epub ahead of print]

27) Kikuchi I, Uchinami H, Nanjo H, et al. Clinical and prognostic significance of urinary trypsin inhibitor in patients with hepatocellular carcinoma after hepatectomy. Ann Surg Oncol. 2009; 16: 2805-17

28) Ryu SH, Chung YH, Lee H, et al. Metastatic tumor antigen 1 is closely associated with frequent postoperative recurrence and poor survival in patients with hepatocellular carcinoma. Hepatology. 2008; 47: 929-36

29) Ding T, Xu J, Wang F, et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol. 2009; 40: 381-9

30) Li YW, Qiu SJ, Fan J, et al. Tumor-infiltrating macrophages can predict favorable prognosis in hepatocellular carcinoma after resection. J Cancer Res Clin Oncol. 2009; 135: 439-49

31) Huang H, Zhang XF, Zhou HJ, et al. Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection. Cancer Sci. 2010; 101: 1314-9

32) Chen RX, Xia YH, Cui JF, et al. Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection. J Gastroenterol Hepatol. 2010; 25: 1435-42

33) Yang GH, Fan J, Xu Y, et al. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist. 2008; 13: 1155-65

34) Schmitz KJ, Wohlschlaeger J, Lang H, et al. Cyclo-oxygenase-2 overexpression is a feature of early and well-differentiated hepatocellular carcinoma with a favourable prognosis. J Clin Pathol. 2009; 62: 690-3

35) He YF, Jin J, Wei W, et al. Overexpression of cyclooxygenase-2 in noncancerous liver tissue increases the postoperative recurrence of hepatocellular carcinoma in patients with hepatitis B virus-related cirrhosis. Can J Gastroenterol. 2010; 24: 435-40

36) Shi YH, Ding WX, Zhou J, et al. Expression of X-linked inhibitor-of-apoptosis protein in hepatocellular carcinoma promotes metastasis and tumor recurrence. Hepatology. 2008; 48: 497-507

37) Tanaka S, Arii S, Yasen M, et al. Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg. 2008; 95: 611-9

38) Budhu A, Jia HL, Forgues M, et al. Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology. 2008; 47: 897-907

39) Lai MW, Huang SF, Lin SM, et al. Expression of the HCRP1 mRNA in HCC as an independent predictor of disease-free survival after surgical resection. Hepatol Res. 2009; 39: 164-76

40) Hu J, Xu Y, Shen ZZ, et al. High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection. J Cancer Res Clin Oncol. 2009; 135: 1359-67

41) Lee HH, Uen YH, Tian YF, et al. Wnt-1 protein as a prognostic biomarker for hepatitis B-related and hepatitis C-related hepatocellular carcinoma after surgery. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1562-9

42) Jia JB, Wang WQ, Sun HC, et al. High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. Oncologist. 2010; 15: 732-43

43) Wang K, Liu J, Yan ZL, et al. Overexpression of aspartyl-(asparaginyl)-beta-hydroxylase in hepatocellular carcinoma is associated with worse surgical outcome. Hepatology. 2010; 52: 164-73

44) Yang XR, Xu Y, Yu B, et al. High expression levels of putative hepatic stem/progenitor cell biomarkers related to tumour angiogenesis and poor prognosis of hepatocellular carcinoma. Gut. 2010; 59: 953-62

45) Chen MS, Li JQ, Zheng Y, et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg. 2006; 243: 321-8

46) Guglielmi A, Ruzzenente A, Valdegamberi A, et al. Radiofrequency ablation versus surgical resection for the treatment of hepatocellular carcinoma in cirrhosis. J Gastrointest Surg. 2008; 12: 192-8

47) Hiraoka A, Horiike N, Yamashita Y. Efficacy of radiofrequency ablation therapy compared to surgical resection in 164 patients in Japan with single hepatocellular carcinoma smaller than 3 cm, along with report of complications. Hepatogastroenterology. 2008; 55: 2171-4

48) Cho YK, Kim JK, Kim WT, et al. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma: a Markov model analysis. Hepatology. 2010; 51: 1284-90

49) Portolani N, Baiocchi GL, Coniglio A, et al. Sequential multidisciplinary treatment of hepatocellular carcinoma: the role of surgery as rescue therapy for failure of percutaneous ablation therapies. J Surg Oncol. 2009; 100: 580-4

50) Abu-Hilal M, Primrose JN, Casaril A, et al. Surgical resection versus radiofrequency ablation in the treatment of small unifocal hepatocellular carcinoma. J Gastrointest Surg. 2008; 12: 1521-6

51) Hasegawa K, Makuuchi M, Takayama T, et al. Surgical resection vs. percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol. 2008; 49: 589-94

52) Molinari M, Helton S. Hepatic resection versus radiofrequency ablation for hepatocellular carcinoma in cirrhotic individuals not candidates for liver transplantation: a Markov model decision analysis. Am J Surg. 2009; 198: 396-406

53) Kim H, Rhim H, Choi D, et al. Recurrence and treatment pattern in long-term survivors with hepatocellular carcinoma: a comparison between radiofrequency ablation and surgery as a first-line treatment. World J Surg. 2010; 34: 1881-6

54) Ueno S, Sakoda M, Kubo F, et al. Surgical resection versus radiofrequency ablation for small hepatocellular carcinomas within the Milan criteria. J Hepatobiliary Pancreat Surg. 2009; 16: 359-66

55) Liang HH, Chen MS, Peng ZW, et al. Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study. Ann Surg Oncol. 2008; 15: 3484-93

56) Zhou Y, Zhao Y, Li B, et al. Meta-analysis of radiofrequency ablation versus hepatic resection for small hepatocellular carcinoma. BMC Gastroenterol. 2010; 10: 78

57) Seror O, N'Kontchou G, Ibraheem M, et al. Large (＞or＝5. 0-cm) HCCs: multipolar RF ablation with three internally cooled bipolar electrodes—initial experience in 26 patients. Radiology. 2008; 248: 288-96

58) Kargozaran H, Wildendorf S, Khatri VP. Radiofrequency-assisted hepatectomy using bipolar inline multichannel radiofrequency device (ILMRD): report of initial clinical experience. Hepatogastroenterology. 2009; 56: 1496-500

59) Meijerink MR, van den Tol P, van Tilborg AA, et al. Radiofrequency ablation of large size liver tumours using novel plan-parallel expandable bipolar electrodes: Initial clinical experience. Eur J Radiol. 2009 Jul 17 [Epub ahead of print]

60) Eisele RM, Neuhaus P, Schumacher G. Radiofrequency ablation of liver tumors using a novel bipolar device. J Laparoendosc Adv Surg Tech A. 2008; 18: 857-63

61) Laspas F, Sotiropoulou E, Mylona S, et al. Computed tomography-guided radiofrequency ablation of hepatocellular carcinoma: treatment efficacy and complications. J Gastrointestin Liver Dis. 2009; 18: 323-8

62) Park BJ, Byun JH, Jin YH, et al. CT-guided radiofrequency ablation for hepatocellular carcinomas that were undetectable at US: therapeutic effectiveness and safety. J Vasc Interv Radiol. 2009; 20: 490-9

63) Kato T, Yamagami T, Hirota T, et al. Transpulmonary radiofrequency ablation for hepatocellular carcinoma under real-time computed tomography-fluoroscopic guidance. Hepatogastroenterology. 2008; 55: 1450-3

64) Livraghi T, Meloni F, Di Stasi M, et al. Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice？ Hepatology. 2008; 47: 82-9

65) N'Kontchou G, Mahamoudi A, Aout M, et al. Radiofrequency ablation of hepatocellular carcinoma: long-term results and prognostic factors in 235 Western patients with cirrhosis. Hepatology. 2009; 50: 1475-83

66) Hiraoka A, Michitaka K, Horiike N, et al. Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients. J Gastroenterol Hepatol. 2010; 25: 403-7

67) Cha J, Rhim H, Lee JY, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma: assessment of safety in patients with ascites. AJR Am J Roentgenol. 2009; 193: W424-9

68) Kashima M, Yamakado K, Takaki H, et al. Radiofrequency ablation for the treatment of bone metastases from hepatocellular carcinoma. AJR Am J Roentgenol. 2010; 194: 536-41

69) Yamakado K, Anai H, Takaki H, et al. Adrenal metastasis from hepatocellular carcinoma: radiofrequency ablation combined with adrenal arterial chemoembolization in six patients. AJR Am J Roentgenol. 2009; 192: W300-5

70) Kuroda H, Kasai K, Kakisaka K, et al. Changes in liver function parameters after percutaneous radiofrequency ablation therapy in patients with hepatocellular carcinoma. Hepatol Res. 2010: 40: 550-4

71) Hirakawa M, Ikeda K, Kawamura Y, et al. Lipiodol and dye at the site of ablation decreases during RFA. Intervirology. 2008; 51: 362-8

72) Fernandes ML, Lin CC, Lin CJ, et al. Prospective study of a 'popping' sound during percutaneous radiofrequency ablation for hepatocellular carcinoma. J Vasc Interv Radiol. 2010; 21: 237-44

73) Latteri F, Sandonato L, Di Marco V, et al. Seeding after radiofrequency ablation of hepatocellular carcinoma in patients with cirrhosis: a prospective study. Dig Liver Dis. 2008; 40: 684-9

74) Imamura J, Tateishi R, Shiina S, et al. Neoplastic seeding after radiofrequency ablation for hepatocellular carcinoma. Am J Gastroenterol. 2008; 103: 3057-62

75) Park Y, Choi D, Lim HK, et al. Growth rate of new hepatocellular carcinoma after percutaneous radiofrequency ablation: evaluation with multiphase CT. Am J Roentgenol. 2008; 191: 215-20

76) Rempp H, Clasen S, Boss A, et al. Prediction of cell necrosis with sequential temperature mapping after radiofrequency ablation. J Magn Reson Imaging. 2009; 30: 631-9

77) Imai K, Beppu T, Nakayama Y, et al. Preoperative prediction of poorly differentiated components in small-sized hepatocellular carcinoma for safe local ablation therapy. J Surg Oncol. 2009; 100: 121-6

78) Lencioni R, Crocetti L, Petruzzi P, et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: A pilot clinical study. J Hepatol. 2008; 49: 217-22

79) Yamakado K, Nakatsuka A, Takaki H, et al. Early-stage hepatocellular carcinoma: radiofrequency ablation combined with chemoembolization versus hepatectomy. Radiology. 2008; 247: 260-6

80) Kagawa T, Koizumi J, Kojima S, et al. Transcatheter arterial chemoembolization plus radiofrequency ablation therapy for early stage hepatocellular carcinoma: comparison with surgical resection. Cancer. 2010; 116: 3638-44

81) Takaki H, Yamakado K, Uraki J, et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm. J Vasc Interv Radiol. 2009; 20: 217-24

82) Peng ZW, Chen MS, Liang HH, et al. A case-control study comparing percutaneous radiofrequency ablation alone or combined with transcatheter arterial chemoembolization for hepatocellular carcinoma. Eur J Surg Oncol. 2010; 36: 257-63

83) Cheng BQ, Jia CQ, Liu CT, et al. Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial. JAMA. 2008; 299: 1669-77

84) Shibata T, Isoda H, Hirokawa Y, et al. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment？ Radiology. 2009; 252: 905-13

85) Morimoto M, Numata K, Kondou M, et al. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010 Jul 29 [Epub ahead of print]

86) Kurokohchi K, Watanabe S, Yoneyama H, et al. A combination therapy of ethanol injection and radiofrequency ablation under general anesthesia for the treatment of hepatocellular carcinoma. World J Gastroenterol. 2008; 14: 2037-43

87) Wong SN, Lin CJ, Lin CC, et al. Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations. AJR Am J Roentgenol. 2008; 190: W187-95

88) Brunello F, Veltri A, Carucci P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: A randomized controlled trial. Scand J Gastroenterol. 2008; 43: 727-35

89) Wakui N, Iida K, Ikehara T, et al. Recurrence incidence of small HCC in cirrhosis patients by ablation versus injection. Hepatogastroenterology. 2010; 57: 195-201

90) Dhanasekaran R, Khanna V, Kooby DA, et al. The effectiveness of locoregional therapies versus supportive care in maintaining survival within the Milan criteria in patients with hepatocellular carcinoma. J Vasc Interv Radiol. 2010; 21: 1197-204

91) Lencioni R, Crocetti L, Petruzzi P, et al. Doxorubicin-eluting bead-enhanced radiofrequency ablation of hepatocellular carcinoma: a pilot clinical study. J Hepatol. 2008; 49: 217-22

92) Lammer J, Malagari K, Vogl T, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010; 33: 41-52

93) Sadick M, Haas S, Loehr M, et al. Application of DC beads in hepatocellular carcinoma: clinical and radiological results of a drug delivery device for transcatheter superselective arterial embolization. Onkologie. 2010; 33: 31-7

94) Dhanasekaran R, Kooby DA, Staley CA, et al. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol. 2010; 101: 476-80

95) Nicolini A, Martinetti L, Crespi S, et al. Transarterial chemoembolization with epirubicin-eluting beads versus transarterial embolization before liver transplantation for hepatocellular carcinoma. J Vasc Interv Radiol. 2010; 21: 327-32

96) Poggi G, Quaretti P, Minoia C, et al. Transhepatic arterial chemoembolization with oxaliplatin-eluting microspheres (OEM-TACE) for unresectable hepatic tumors. Anticancer Res. 2008; 28: 3835-42

97) Grosso M, Vignali C, Quaretti P, et al. Transarterial chemoembolization for hepatocellular carcinoma with drug-eluting microspheres: preliminary results from an Italian multicentre study. Cardiovasc Intervent Radiol. 2008; 31: 1141-9

98) Woo HY, Bae SH, Park JY, et al. A randomized comparative study of high-dose and low-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol. 2010; 65: 373-82

99) Eun JR, Lee HJ, Moon HJ, et al. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis. Scand J Gastroenterol. 2009; 44: 1477-86

100) Nagamatsu H, Hiraki M, Mizukami N, et al. Intra-arterial therapy with cisplatin suspension in lipiodol and 5-fluorouracil for hepatocellular carcinoma with portal vein tumour thrombosis. Aliment Pharmacol Ther. 2010; 32: 543-50

101) Hirooka M, Koizumi Y, Kisaka Y, et al. Mass reduction by radiofrequency ablation before hepatic arterial infusion chemotherapy improved prognosis for patients with huge hepatocellular carcinoma and portal vein thrombus. AJR Am J Roentgenol. 2010; 194: W221-6

102) Llovet JM, Ricci S, Mazzaferro V, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359: 378-90

103) Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10: 25-34

104) Zhang T, Ding X, Wei D, et al. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials. Anticancer Drugs. 2010; 21: 326-32

105) Wörns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J Clin Gastroenterol. 2009; 43: 489-95

106) Kim JW, Lee JO, Han SW, et al. Clinical outcomes of sorafenib treatment in patients with metastatic hepatocellular carcinoma who had been previously treated with fluoropyrimidine plus platinum-based chemotherapy. Am J Clin Oncol. 2010 Mar 19 [Epub ahead of print]

107) Richly H, Schultheis B, Adamietz IA, et al. Combination of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma: results from a phase I extension trial. Eur J Cancer. 2009; 45: 579-87

108) Hoffmann K, Glimm H, Radeleff B, et al. Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation -HeiLivCa [ISRCTN24081794]. BMC Cancer. 2008; 8: 349

109) Hsu CH, Shen YC, Lin ZZ, et al. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma. J Hepatol. 2010; 53: 126-31

110) Vincenzi B, Santini D, Russo A, et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010; 15: 85-92

111) Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer. 2009; 115: 428-36

112) Maksimovic O, Schraml C, Hartmann JT, et al. Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment. AJR Am J Roentgenol. 2010; 194: 5-14

113) Koeberle D, Montemurro M, Samaras P, et al. Continuous sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77/06). Oncologist. 2010; 15: 285-92

114) Bekaii-Saab T, Markowitz J, Prescott N, et al. A multi-institutional phase II study of the efficacy and tolerability of lapatinib in patients with advanced hepatocellular carcinomas. Clin Cancer Res. 2009; 15: 5895-901

115) Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol. 2009; 27: 843-50

116) Hsu CH, Yang TS, Hsu C, et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer. 2010; 102: 981-6

117) Pinter M, Wichlas M, Schmid K, et al. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur J Gastroenterol Hepatol. 2008; 20: 1012-9

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp